Pre-clinical research from a top preclinical Contract Research Organization in Eastern Europe.
Our company is an independent Contract Research Organization based in the U.S. that provides pre-clinical drug research in top-notch, Good Laboratory Practices certified testing sites in Kiev, Ukraine. Our research laboratories are sponsored by the UNAMS and Health Department and offer services for for-profit development of new drug discoveries as part of their main mission. The CRO was founded to offer the high quality, low-cost services of these research sites to emerging biotech companies in the USA and Europe, thereby providing them with a smart option for promoting development programs rapidly and at much lower cost than other commercial CROs. We provide a broad range of preclinical studies including medicine safety, chronic and acute toxicity, pharma screening, bioavailability, bioequivalence, and complete in vivo and in vitro screening for anti-cancer activity.
Our preclinical Contract Research Organization is able to price pre-clinical testing far below other Contract Research Organizations since we have a very low overhead in the United States and conduct all research in Ukraine where labor and lab costs are much lower. Our staff in the United States is comprised of only of the company principals who work directly with clients; we don’t have any promotion expenses aside from our site, and no head offices, supporting staff or other overhead to inflate costs. We have much lower study conduct prices in Ukraine due to much lower personnel rates and are able to provide our best rates for long-term and more intricate pre-clinical studies where labor is the most significant portion of the overall cost. Since we utilize the same reliable international providers for lab animals, reagents and lab supplies as other CROs, we have no cost savings on these items and thus less overall cost savings for very short-term preclinical tests. But, regardless of your test protocol and length, our goal is to give our customers the best possible value for their investment.